{"provider_name":"Hatena Blog","provider_url":"https://hatena.blog","html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Fpharma-stat.hatenablog.jp%2Fentry%2F2021%2F08%2F16%2F180041\" title=\"ADaM Spec\u3092\u66f8\u3053\u3046\uff01(1)Define.XML\u3068\u306f - RINSTA\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","title":"ADaM Spec\u3092\u66f8\u3053\u3046\uff01(1)Define.XML\u3068\u306f","categories":["CDISC"],"width":"100%","version":"1.0","description":"CDISC\u6848\u4ef6\u306a\u3089\u907f\u3051\u3066\u901a\u308c\u306a\u3044ADaM Spec\u3002\u305d\u306eADaM Spec\u3092\u4f5c\u6210\u3059\u308b\u305f\u3081\u306b\u5fc5\u8981\u306a\uff0cDefine.XML\u306e\u77e5\u8b58\u3092\u307e\u3068\u3081\u307e\u3059\u3002","author_url":"https://blog.hatena.ne.jp/pharma_stat/","blog_url":"https://pharma-stat.hatenablog.jp/","url":"https://pharma-stat.hatenablog.jp/entry/2021/08/16/180041","author_name":"pharma_stat","blog_title":"RINSTA","published":"2021-08-16 18:00:41","height":"190","image_url":null,"type":"rich"}